Anti-tumor immune response after photodynamic therapy

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 7380, Issue , 2009, Pages

  Mroz, Pawel ^a,b   Castano, Ana P ^a,b   Wu, Mei X ^a,b,c   Kung, Andrew L ^d   Hamblin, Michael R ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

colon cancer; cytotoxic T cells; low dose cyclophosphamide; photodynamic therapy; regulatory T cells; tumor associated antigen

Indexed keywords

COLON CANCER; CYTOTOXIC; LOW DOSE; T CELLS; TUMOR-ASSOCIATED ANTIGEN;

ANTIGENS; BODY FLUIDS; CELLS; CHROMIUM; CURING; CYTOLOGY; DISEASES; IMMUNOLOGY; MAMMALS; PLASMONS; TUMORS;

PHOTODYNAMIC THERAPY;

EID: 79959575434     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.822994     Document Type: Conference Paper

References (20)

1. Hamblin, M. R., and Mroz, P. Advances in photodynamic therapy: basic, translational and clinical. Norwood, MA: Artech House, 2008.
2. Castano, A. P., Demidova, T. N., and Hamblin, M. R., "Mechanisms in photodynamic therapy: part one - photosensitizers, photochemistry and cellular localization," Photodiagn Photodyn Ther. 1, 279-293 (2004)
3. Canti, G., Lattuada, D., Nicolin, A., Taroni, P., Valentini, G., and Cubeddu, R., "Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light," Anticancer Drugs. 5, 443-447 (1994)
4. Castano, A. P., Mroz, P., and Hamblin, M. R., "Photodynamic therapy and anti-tumour immunity," Nat Rev Cancer. 6, 535-545 (2006)
5. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T., "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma," Science. 254, 1643-1647 (1991)
6. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A., "Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?," J Natl Cancer Inst. 94, 805-818 (2002)
7. Wang, M., Bronte, V., Chen, P. W., Gritz, L., Panicali, D., Rosenberg, S. A., and Restifo, N. P., "Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen," J Immunol. 154, 4685-4692 (1995)
8. McCabe, B. J., Irvine, K. R., Nishimura, M. I., Yang, J. C., Spiess, P. J., Shulman, E. P., Rosenberg, S. A., and Restifo, N. P., "Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses," Cancer Res. 55, 1741-1747 (1995)
9. Marzo, A. L., Lake, R. A., Robinson, B. W., and Scott, B., "T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors," Cancer Res. 59, 1071-1079 (1999)
10. Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., Pardoll, D. M., and Jaffee, E. M., "The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product," Proc Natl Acad Sci U S A. 93, 9730-9735 (1996)
11. Wang, M., Chen, P. W., Bronte, V., Rosenberg, S. A., and Restifo, N. P., "Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen," J Immunother Emphasis Tumor Immunol. 18, 139-146 (1995)
12. Dal Porto, J., Johansen, T. E., Catipovic, B., Parfiit, D. J., Tuveson, D., Gether, U., Kozlowski, S., Fearon, D. T., and Schneck, J. P., "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations," Proc Natl Acad Sci U S A. 90, 6671-6675 (1993)
13. Andersson, J., Tran, D. Q., Pesu, M., Davidson, T. S., Ramsey, H., O'Shea, J. J., and Shevach, E. M., "CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner," J Exp Med. 205, 1975-1981 (2008)
14. Castano, A. P., Mroz, P., Wu, M. X., and Hamblin, M. R., "Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model," Proc Natl Acad Sci U S A. 105, 5495-5500 (2008)
15. Carroll, M. W., Overwijk, W. W., Chamberlain, R. S., Rosenberg, S. A., Moss, B., and Restifo, N. P., "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model," Vaccine. 15, 387-394 (1997)
16. Irvine, K. R., Rao, J. B., Rosenberg, S. A., and Restifo, N. P., "Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases," J Immunol. 156, 238-245 (1996)
17. McElrath, M. J., Corey, L., Berger, D., Hoffman, M. C., Klucking, S., Dragavon, J., Peterson, E., and Greenberg, P. D., "Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting," J Infect Dis. 169, 41-47 (1994)
18. Graham, B. S., Matthews, T. J., Belshe, R. B., Clements, M. L., Dolin, R., Wright, P. F., Gorse, G. J., Schwartz, D. H., Keefer, M. C., Bolognesi, D. P., and et al., "Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network," J Infect Dis. 167, 533-537 (1993)
19. McWilliams, J. A., Sullivan, R. T., Jordan, K. R., McMahan, R. H., Kemmler, C. B., McDuffie, M., and Slansky, J. E., "Age-dependent tolerance to an endogenous tumor-associated antigen," Vaccine. 26, 1863-1873 (2008)
20. Lutsiak, M. E., Semnani, R. T., De Pascalis, R., Kashmiri, S. V., Schlom, J., and Sabzevari, H., "Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide," Blood. 105, 2862-2868 (2005)